Application of plasma S100A12 in early diagnosis of ST segment elevation myocardial infarction

Abstract

The invention belongs to the technical field of medical biology, and particularly relates to application of plasma S100A12 in early diagnosis of ST segment elevation myocardial infarction (STEMI). The S100A12 is a member of the calcium binding protein family which is mainly secreted from myocardial cells, vascular smooth muscle cells of vascular wall atherosclerosis plaque and blood neutrophils. The S100A12 is protein having molecular weight of 12KD, contains 2 EF chiral calcium ion binding areas, and can be quickly released into circulating blood from myocardial cells, vascular smooth muscle cells and blood neutrophils after acute myocardial infarction happens due to the relatively small molecular weight, and expression level increase of S100A12 can be detected in early (in 30 minutes of chest pain) of occurrence of acute myocardial infarction, and the S100A12 can be used as a biomarker for STEMI early diagnosis.

Description

technical field [0001] The invention belongs to the technical field of medical biology, and particularly relates to the application of plasma S100A12 in the early diagnosis of ST-segment elevation myocardial infarction, specifically the application of S100A12 protein in the very early diagnosis of ST-segment elevation myocardial infarction (STEMI). Background technique [0002] Acute myocardial infarction is one of the common and important diseases that seriously threaten human health. Acute myocardial infarction, especially ST-segment elevation myocardial infarction, has an acute onset, and the morbidity and mortality continue to increase. Early diagnosis and reperfusion therapy are the key to improving the survival rate of acute myocardial infarction. The World Health Organization stipulates that the diagnosis of acute myocardial infarction is based on clinical symptoms of chest pain, changes in the electrocardiogram, and increases in biomarkers such as myocardial enzymes....

AI Technical Summary

Problems solved by technology

[0003] At present, traditional biomarkers have their own defects. Although CK-MB is the gold standard for diagnosing STEMI patients, its sensitivity is poor and it does not increase in the early stage of onset (within 4 hours before onset). In 1990, a large number of clinical studies confirmed that, Troponin (TnT, TnI) can be used for the early diagnosis of STEMI and the evaluation of the condition. The American College of Cardiology / American Heart Association revised the diagnostic criteria for STEMI and included troponin as a myocardial marker for the diagnosis of STEMI , the definition of STEMI is updated to myocardial markers, especially when the increase of troponin reaches the cut-off value of myocardial injury, it can be diagnosed as STEMI

However, troponin starts to increase 3-4 hours after onset and reaches its peak in 10-24 hours, which has limited significance for early diagnosis of STEMI patients; CK-MB and troponin increase in the early onset (3 hours after onset) of STEMI patients Small, low diagnostic efficiency, myoglobin begins to increase 1 hour after the onset of STEMI, but the diagnostic specificity is low, and it is often necessary to combine other indicators to diagnose STEMI

Clinically, about 1 / 3 of STEMI patients have atypical early clinical symptoms and electrocardiographic manifestations, and the myocardial injury markers currently used clinically have the above-mentioned deficiencies, CK-MB rises later, and the diagnostic sensitivity is low; The protein cannot be detected within 2 hours of the onset of STEMI; although myoglobin begins to increase 1-2 hours after the onset of STEMI, it has poor specificity and has no independent diagnostic value

Images